Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c
Tweet
Share
E-mailGet Alerts DNTH Hot Sheet
Join SI Premium – FREE
Dianthus Therapeutics (NASDAQ: DNTH) reported Q2 EPS of ($0.09), $0.77 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $297.42 thousand.
For earnings history and earnings-related data on Dianthus Therapeutics (DNTH) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Futu Holdings Limited (FUTU) Tops Q2 EPS by 23c
- JPMorgan Reiterates Overweight Rating on Marvell (MRVL)
- NexPoint Residential Trust (NXRT) Reiterated at Market Perform by Citizens Post Guidance Cut
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
